Skip to main content

Visual and rapid detection of Acinetobacter baumannii by a multiple cross displacement amplification combined with nanoparticles-based biosensor assay


The traditional microbiological methods used for detecting Acinetobacter baumannii were usually time-consuming and labor-intensive. Thus, we sought to establish a novel rapid detecting method for target pathogen. A set of multiple cross displacement amplification (MCDA) primers was designed to recognize 10 different regions of the pgaD gene, which was conservative and specific for the bacterium. In the MCDA system, amplification primers D1 and R1 were 5′-labeled with FITC (fluorescein) and biotin, respectively. Numerous FITC- and biotin-attached duplex amplicons were formed during the amplification stage, which were detected by nanoparticles-based lateral flow biosensors (LFB) through immunoreactions (FITC on the duplex and anti-FITC on the LFB test line) and biotin/streptavidin interaction (biotin on the duplex and streptavidin on the nanoparticles). The results showed that the optimized reaction condition of MCDA-LFB method was 62 °C within 25 min. There was no cross reaction with non-A. baumannii species and the non-Acinetobacter genera, and the detection limit for DNA samples was 100 fg/reaction. For 135 sputum samples, the detection results showed that the detection ability of MCDA-LFB assay was superior to the culture methods and conventional PCR. Therefore, MCDA-LFB assay could be a potential tool for the rapid detection of A. baumannii in clinical samples and low resource areas.


Acinetobacter baumannii (A. baumannii), a strict-aerobic, gram-negative, rod-shaped, opportunistic pathogen, extensively exists in natural and medical environments (Bergongne-Berezin and Towner 1996; Van Looveren and Goossens 2004). In addition to responsible for respiratory tract infections and bacteremia, the organism also can cause urinary tract infection, secondary meningitis, peritonitis, and other types of infections, especially in immune-compromised patients and those patients who undergo invasive procedures (Marioni et al. 2010; Antunes et al. 2014; Zhou et al. 2014). Due to the lack of specific clinical symptoms and rapid diagnostic techniques, antibiotics in the early stage of A. baumannii infection can only be used experientially, which maybe overused or misused. As a result, a number of multidrug-resistant (MDR) A. baumannii strains appeared, even the emergence of extensively-drug resistant (XDR) and pandrug-resistant (PDR) strains that posed a difficult problem to clinical treatment, particularly in critically ill patients (Durante-Mangoni and Zarrilli 2011). Therefore, it is of vital to establish a rapid and accurate diagnosis method for guiding the appropriate therapy of A. baumannii in the early infection stage.

The gold standard used for diagnosis of A. baumannii infection is traditional culture-biochemical methods, which usually takes 24–72 h of incubation to produce positive results, and thus is typically labor intensive and time consuming. Consequently, this technique could not satisfy early detection of causative pathogens, which is crucial for the proper use of antimicrobial agents. Recently, a number of nucleic acid test methods were developed to detect and identify A. baumannii. PCR based on 16S–23S ribosomal DNA intergenic spacer region and recA gene were carried out to detect A. baumannii (Chiang et al. 2011). Real-time PCR systems based on ompA, blaoxa51, bfs and bap gene have also been used for its specific identification (Nomanpour et al. 2011; Zhang et al. 2011; McConnell et al. 2012; De Gregorio et al. 2015). In addition, Linear-after-the-exponential PCR based on gyrB gene has also been developed for confirming its specificity (Rice et al. 2013). However, these molecular methods require specialized high-cost equipment, which are not readily available in low-resource settings and outbreak control. Moreover, most of these genes could not effectively distinguish A. baumannii from Acinetobacter pittii (Acinetobacter genospecies 3), Acinetobacter nosocomialis (Acinetobacter genospecies 13TU) and Acinetobacter lwoffii, which have been recognized as important nosocomial pathogens recently (Dijkshoorn et al. 2007; Higgins et al. 2007; Turton et al. 2010). Thus, another rapid, simple and specific assay detecting the other target gene is required to replace current PCR assays.

Multiple cross displacement amplification (MCDA) method, a new nucleic acid amplification technique, which eliminated a thermocycler or sophisticated training, could be conducted at a constant temperature (60–67 °C) within 40 min (Wang et al. 2015). There are ten specific primers to recognize distinct regions of the target sequence. After termination of amplification, the gold nanoparticle-based lateral flow biosensors (LFB), a very suitable diagnosis technique, has been designed and applied to MCDA-amplified products detection (Wang et al. 2017).

In this study, MCDA technique coupled with LFB was developed for rapid and sensitive detection of A. baumanni at pgaD gene. pgaD is a specific and conservative sequences of A. baumannii, and encodes proteins that synthesize cell-associated poly-b-(1-6)-N-acetylglucosamine (PNAG) (Choi et al. 2009; Wang et al. 2013). In the study, ten specific primers targeting different sites of A. baumannii-pgaD gene were designed, and the condition of these primers in MCDA reaction was optimized. The specificity and sensitivity of the MCDA-LFB method for the detection of A. baumanni were evaluated. Finally, clinical samples of A. baumannii were identified by MCDA-LFB method, which was compared with the culture method and also with the conventional PCR method.

Materials and methods

Bacterial strains and genomic DNA preparation

A total of 43 bacterial strains were used in this study (Table 1). Species identification were carried out initially by using Gram’s method, microscopy, oxidase experiment, and further confirmed by DL-96 systems using 96E ID Card according to the manufacturers instructions. The identification results are showed automatically by accompanying software (culture and biochemical methods). Genomic DNA was extracted from the respective bacteria using a DNA Mini Kit, and extracted DNA was quantified with ultraviolet spectrophotometer (Nano drop one, Thermo, Beijing, China) at A260/280. A. baumannii strain ATCC19606 DNA was used for confirmation MCDA products, optimal amplification temperature, optimal detection time and sensitivity analysis, while DNA from Klebsiella pneumoniae strain ATCC700603 and Pseudomonas aeruginosa strain THH-PA001 were used as negative controls.

Table 1 Strains used and the results of MCDA assays


QIAamp DNA Mini Kits and QIAamp DNA Microbiome Kits were purchased from Qiagen Co., ltd. (Beijing, China). The isothermal amplification kits, Lateral flow biosensors (LFB) and Malachite Green (MG) was purchased from BeiJingHaiTai-ZhengYuan Technology Co., Ltd. (Beijing). PCR MasterMix reagents were purchased from Tiangen Biotech Co., Ltd. (Beijing).

Primer design

A set of MCDA primers, including two displacement primers (F1 and F2), two cross primers (CP1 and CP2) and six amplification primers (C1, C2, D1, D2, R1 and R2), were designed based on the sequence of pgaD coding region by PRIMER PREMIER 5.0 and PrimerExplorer V4 ( All hybrids and hairpin structures of MCDA primers were analyzed by the Integrated DNA Technologies design tool ( Blast analysis was applied for confirming that all MCDA primers were specific for targeting A. baumannii. In order to detect MCDA products by LFB, the D1 and R1 primers were 5′-labeled with fluorescein (FITC) and biotin, respectively. The details of location, sequences and modifications of primers are listed in Fig. 1 and Table 2. All of the oligomers were synthesized and purified by TsingKe Biotech Co., Ltd. (Beijing, China) at HPLC purification grade.

Fig. 1

Schematic diagram of MCDA primer design for pgaD gene

Table 2 The primers used in this study

The MCDA assay

The MCDA reactions were carried out in a total of 25 μL reaction mixtures, and the amount of primer required for one reaction was 0.4 μmol L−1 displacement primers F1 and F2; 0.8 μmol L−1 amplification primers C1, C2, D1*, D2, R1*, and R2; 1.6 μmol L−1 cross primer CP1 and CP2; In addition, 1 μL Bst DNA polymerase (10 U), 12.5 μL 2XReaction Buffer, 1.5 μL Malachite Green and 1 μL of DNA template were also added to the amplification mixes. At the same time, 10 ng genome DNA of klebsiella pneumoniae ATCC700603 and Pseudomonas aeruginosa THH-PA001 were used as negative control, and 1 μL of double distilled water (DW) was used as blank control. Conventional PCR was performed as described previously (Wang et al. 2013).

Three monitoring methods, including colorimetric indicator (MG), gel electrophoresis and LFB, were used to analyze MCDA amplicons. When using MG, the amplified products cause a color change in the reaction solution from green to bright green, while the reaction solution of the negative controls and blank control without amplification turned colorless. In electrophoresis, a ladder-like band is observed for positive amplifications, but not in negative controls and blank control. By LFB, both the test line (TL) and the control line (CL) were observed for positive reactions, but only the CL was visualized in negative controls and blank control.

To validate the feasibility of MCDA primers, the reactions were initially incubated at 62 °C for 20 min and then inactived by heating at 85 °C for 2 min. To determine the optimal reaction temperature, eight distinct temperatures ranging from 60 to 67 °C at 1 °C interval were monitored in the Real-time Turbidimeter, and on the basis of the optimal reaction temperature, the MCDA mixture was incubated from 10 to 25 min with 5 min intervals to ensure the shortest time for LFB detection.

Specificity and sensitivity of LFB assay for detecting A. baumanni-MCDA products

Genomic DNA of A. baumanni strain ATCC19606 diluted from 10 ng μL−1 to 1 fg μL−1 were prepared in DW to define the detection limit of MCDA-LFB assays. 1.0 μL DNA was used as template for per reaction, and each reaction was repeated at least twice. Detection of A. baumanni-MCDA products by LFB assay was compared to the methods of agarose gel electrophoresis and colorimetric indicator for three replicates.

Twenty-one A. baumanni strains and twenty-two non-A. baumanni strains were used to confirm the specificity of the MCDA-LFB assay. Each reaction was repeated three times.

Application of MCDA-LFB assay in clinical sputum samples

To explore the clinical application value of the A. baumanni-MCDA-LFB assay, 135 clinical sputum samples were collected from Taihe (Shiyan, Hubei, China) hospitalized patients with cough or pneumonia and healthy people, which were first discriminated by the reference method, and then assessed by conventional PCR and MCDA-LFB established in this study. The reference method are the same as the above description of species identification. The PCR primer sequences used were: PgaD forward 5′-TGT TTA ATG TGG CTG CTT T-3′, and PgaD reverse 5′-CAG TCA TGG CTT AGT AAT AGT-3′. PCR reactions were conducted in a total of 20 μL volume containing 0.5 μM PgaD forward and PgaD reverse primer each, 10 μL 2XTaq PCR MasterMix II, 7 μL DW and 1 μL of DNA as the template. Reaction conditions were set at 93 °C for 3 min, followed by 35 cycles of 93 °C for 15 s, 53 °C for 15 s, 72 °C for 15 s, with a final extension at 72 °C for 5 min. The PCR products were then analyzed by 1.5% agarose gel electrophorsis.


Determination of A. baumanni-MCDA products

The effectiveness of the MCDA primers targeting A. baumanni-pgaD gene were evaluated by three groups at 62 °C for 20 min, including positive control (A. baumanni), negative control (Klebsiella pneumoniae and Pseudomonas aeruginosa) and blank control (DW). Three diagnosis methods were used to analyze MCDA products, such as Malachite Green, agarose gel electrophoresis and LFB. The reference strain ATCC19606 DNA produced positive results as shown in Fig. 2, the color of reaction mixture turned bright green at the end of amplification, two red bands were visible on the control line and the test line of a LFB, and a ladder-like band occurred on 2% gel electrophoresis. However, the DNA from klebsiella pneumoniae ATCC700603, Pseudomonas aeruginosa THH-PA001 or the blank control produced negative results as follows: (i) the reaction mixture without amplicons turned colorless, (ii) only a single red band appeared on the biosensor control line, (iii) no ladder-like bands arise. Therefore, these results indicated that the primer set designed in the current study was a good candidate for establishment of MCDA-LFB approach for A. baumanni detection.

Fig. 2

Determining of A. baumanni-MCDA products. a 1.5 μL of Malachite Green added to 25 μL of MCDA reaction mixture before the MCDA reaction was used to identify amplification products of the A. baumanni-MCDA assay; b Lateral flow biosensor (LFB) applied for visual detection of A. baumanni-MCDA products; c The A. baumanni-MCDA products were analyzed using agarose gel electrophoresis. Lane M, DNA maker DL1000. Tube/Biosensor/Lane: 1, positive amplification of A. baumanni strain ATCC19606; 2, negative control (Klebsiella pneumoniae strain ATCC700603); 3, negative control (THH-PA001); 4, blank control (DW). TL, test line. CL, control line

The optimal temperature assessed for MCDA assay

In order to obtain the optimal temperature of the primers in the MCDA reaction, we adopted a real-time turbidity to monitor amplification state of the reference strain DNA at eight different temperatures (ranging from 60 °C to 67 °C at 1 °C interval) for 1 h. The result showed that the MCDA products at 62 °C displayed the highest level of amplified amount of pgaD gene with shortest time than that at other temperatures as observed in Fig. 3.

Fig. 3

Optimization amplification temperature for A. baumannii-MCDA primers. MCDA reactions for detection of A. baumannii were monitored by real-time measurement of turbidity and the corresponding curves of DNA concentration were marked in the diagram. Turbidity of > 0.1 was considered positive. Kinetic curves (ah) were generated at 60–67 °C (1 °C intervals) respectively with 1 pg DNA per reaction

The detection limit of A. baumanni-MCDA-LFB assays

In order to know the detection limit of MCDA-LFB assay, eight different concentrations (ranging 10 ng μL−1 to 1 fg μL−1) of A. baumanni strain ATCC19606 DNA were respectively amplified at 62 °C for 20 min, and a red band appeared in the LFB test line with the detection limit being 100 fg μL−1 in 2 min. As observed in Fig. 4, the miniumu amount of Malachite Green assay or gel electrophoresis assay for A. baumanni-MCDA products was also 100 fg per reaction, which was in complete accordance with LFB detection.

Fig. 4

The detection limit of A. baumanni-MCDA-LFB assays. Three measurement techniques, including colorimetric indicator (a), gel electrophoresis (b) and lateral flow biosensor (c), were applied for analysis of MCDA amplicons. Serial dilutions of the template (10 ng, 100 pg, 10 pg, 1 pg, 100 fg, 10 fg and 1 fg) were subjected to standard MCDA reactions. Tubes (a), lanes (b), biosensors (c) 1–8 respectively represent A. baumannii strain ATCC19606 DNA levels of 10 ng, 100 pg, 10 pg, 1 pg, 100 fg, 10 fg and 1 fg per reaction, and a blank control (DW)

The optimal detection time of LFB assay for A. baumanni-MCDA products

As observed in Fig. 5, when MCDA lasted for 10 min, only the control line was observed in a LFB; When MCDA lasted for 15 min, only the amplified products of the initial DNA level of 1 pg above produced postive results; When MCDA amplified for 20 min and 25 min, the limit of detection were both 100 fg by LFB, so the optimal reaction time for LFB to detect the amplified products was 20 min.

Fig. 5

Optimal detection time required for A. baumanni MCDA-LFB assay. Four different reaction times (a 10 min; b 15 min; c 20 min; d 25 min) were evaluated at 62 °C. Biosensors 1–8 represent A. baumanni strain ATCC19606 DNA levels of 10 ng, 100 pg, 10 pg, 1 pg, 100 fg, 10 fg and 1 fg per reaction, and a blank control (DW), repectively. The best sensitivity was observed when MCDA lasted for 20 min (c)

Specificity of LFB assays detecting A. baumanni-MCDA products

To confirm the specificity of LFB assay for A. baumanni-MCDA products, DNA were respectively extracted from 21 A. baumanni strains and 22 non-A. baumanni strains, and then were amplified under the optimized conditions. As shown in Table 1 and Fig. 6, LFB assays for A. baumanni-MCDA products did not cause cross reaction with non-A. baumannii species and the non-Acinetobacter genera but A. baumanni, indicating that LFB assay was highly select and specific for A. baumannii-MCDA products.

Fig. 6

Specificity of LFB assays detecting A. baumanni-MCDA products. Different genomic DNA templates extracted from 43 strains were analyzed by MCDA-LFB assays. Two red lines were visuable in LFB for all A. baumannii, and only the control line was observed in non-A. baumannii. 1, Positive control (A. baumannii ATCC19606), 2–21, isolated A. baumannii strains. 22, Acinetobacter nosocomialis; 23, Acinetobacter pittii; 24, Acinetobacter lwoffii; 25, Pseudomonas aeruginosa THH-PA001; 26, klebsiella pneumoniae ATCC700603; 27, Haemophilus influenza; 28, Haemophilus parahaemolyticus; 29, Mycobacterium tuberculosis ATCC25177; 30, Neisseria meningitides ATCC13090; 31–32, Streptococcus pneumoniae; 33, Staphylococcus aureus; 34, Staphylococcus epidemidis; 35, Staphylococcus saprophyticus; 36, Vibrio cholera; 37, Salmonella; 38, Listeria monocytogenes ATCC51779; 39, Enterohemorrhagic E. coli; 40, Enteropathogenic E. coli; 41, Enterotoxigenic E. coli; 42, Enteroaggregative E. coli; 43, Enteroinvasive E. coli

Application of MCDA-LFB assay in clinical sputum samples

To further confirm whether MCDA-LFB assay could be applied in clinical samples, a total of 135 sputum samples, including 130 sputum samples collected from patients and 5 sputum samples collected from healthy controls, were detected. Of the 130 clinical sputum samples, MCDA-LFB assays detected 30 positive samples, which contain 26 sputum samples that have been confirmed positive by conventional PCR, and 22 confirmed by the culture assays. No positive results were determined from healthy controls (Negative control) by three detecting methods (Table 3). The MCDA-LFB assay showed 100% sensitivity, 92.9% specificity, 73.7% positive predictive value and 100% negative predictive value when compared to Culture-based assay. The MCDA-LFB assay showed 100% sensitivity, 96.3% specificity, 86.7% positive predictive value and 100% negative predictive value when compared to PCR assay.

Table 3 Comparison of methods for detection of A. baumannii in sputum samples


In the present study, a new amplification technique MCDA combined with the LFB assay was developed for rapid detection of A. baumanni. To date, the MCDA-LFB assay also had been successfully applied to the rapid detection of Staphylococcus aureus, Klebsiella pneumoniae and Pseudomonas aeruginosa (Wang et al. 2018a, b; Zhao et al. 2018). In addition to its high specificity, the MCDA-LFB assay could detect as low as 100 fg A. baumannii DNA, which was as sensitive as the A. baumannii–LAMP method, the limit detection of which was also 100 fg (Soo et al. 2013).

The detection methods used for analysis of MCDA products rely mainly on agarose gel electrophoresis, real-time turbidity, colorimetric indicator and LFB. The test of MCDA products by agarose gel electrophoresis needs an additional gel imaging system, which limits its application in low resource areas, and so does the expensive real-time turbidity. Another diagnosis method colorimetric indicator is somewhat subjective as the insufficient amplicons may lead to ambiguous judgment. Particularly, LFB avoids these disadvantages, easy to conduct, carry and the cost it takes only $US 2, eliminating the tedious gel electrophoresis, the use of hazardous EB and special devices, detecting the amplicons by observing whether the control line and the test line simultaneously appeared on the biosensor within 2 min. Hence, indicating MCDA result by LFB is objective, simple and rapid. In addition, electrophoresis, real-time turbidity and colorimetric indicator could not effectively differentiate specific amplicons from non-specific amplicons when MCDA generated a complex mixture of various amplicons, because a total of ten primers were employed for MCDA reaction system. In this report, we employed LFB for reporting the amplification results, which depends on anti-FITC on the LFB test line specially capturing FITC on the duplex. As a result, LFB analysis effectively overcomes this problem caused by non-specific DNA amplification, and further increases specificity on the basis of MCDA reaction. Therefore, LFB is more suitable for determining MCDA products.

The results of clinical specimens detection demonstrated that MCDA-LFB assays with the detection rate by 23.1% were more sensitive than conventional PCR of 20% and culture methods of 16.9%. The reason may be that culture assays could only be done in the situation of viable bacterial in the collected samples, so the death of strains would lead to false-negative results. However, DNA-based detection assays can avoid this problem, which is conducted in pathogen, alive or dead. Here, conventional PCR failed to amplify some samples that were confirmed positive by MCDA-LFB assays, may be due to lower amounts of bacterial templates. Moreover, the cost of each MCDA-LFB test is affordability with about $US 5.5, including MCDA per reaction with $US 3 and a LFB with $US 2. Besides, the only required instrument for the MCDA-LFB system is a constant temperature heater, such as a dry block heater with 1 kg, which is very portable, and in the whole operation process, no special training or a certified laboratory was required. Herein, the run cost declines.

In conclusion, we successfully developed a rapid, convenient, specific, sensitive, visual, free of special equipment and low cost MCDA-LFB assay for A. baumannii detection in clinical lower respiratory tract samples at 62 °C within 25 min getting rid of sample handling, which can be a valuable tool for surveillance and diagnosis of A. baumannii in the early infection stage, especially in routine detection, field use and resource constrained settings. Later, we will research on other clinical sample types using MCDA-LFB assay, including blood, urine, throat swabs and wounds, to further validate the practicability of the A. baumannii MCDA-LFB assay. To go a step further, we will study the rapid detection of drug resistance genes of A. baumannii on the basis of A. baumannii MCDA-LFB assay established in this study, to lay the foundation for developing a set of multi-channel rapid detection of multiresistant A. baumannii.


  1. Antunes LC, Visca P, Towner KJ (2014) Acinetobacter baumannii: evolution of a global pathogen. Pathog Dis 71(3):292–301.

    CAS  Article  PubMed  Google Scholar 

  2. Bergongne-Berezin E, Towner KJ (1996) Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 9(2):148–165

    Article  Google Scholar 

  3. Chiang MC, Kuo SC, Chen YC, Lee YT, Chen TL, Fung CP (2011) Polymerase chain reaction assay for the detection of Acinetobacter baumannii in endotracheal aspirates from patients in the intensive care unit. J Microbiol Immunol Infect 44(2):106–110.

    Article  PubMed  Google Scholar 

  4. Choi AH, Slamti L, Avci FY, Pier GB, Maira-Litra´n T (2009) The pgaABCD locus of Acinetobacter baumannii encodes the production of poly-beta-1-6-N-acetylglucosamine, which is critical for biofilm formation. J Bacteriol 191(19):5953–5963.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  5. De Gregorio E, Roscetto E, Lula VD, Martinucci M, Zarrilli R, Di Nocera PP, Catania MR (2015) Development of a real-time PCR assay for the rapid detection of Acinetobacter baumannii from whole blood samples. New Microbiol 38(2):251–257

    PubMed  Google Scholar 

  6. Dijkshoorn L, Nemec A, Seifert H (2007) An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 5(12):939–951

    CAS  Article  Google Scholar 

  7. Durante-Mangoni E, Zarrilli R (2011) Global spread of drug-resistant Acinetobacter baumannii: molecular epidemiology and management of antimicrobial resistance. Future Microbiol 6(4):407–422.

    Article  PubMed  Google Scholar 

  8. Higgins PG, Wisplinghoff H, Krut O, Seifert H (2007) A PCR-based method to differentiate between Acinetobacter baumannii and Acinetobacter genomic species 13TU. Clin Microbiol Infect 13(12):1199–1201

    CAS  Article  Google Scholar 

  9. Marioni G, Marchese-Ragona R, Boldrin C, Parisi SG, Vianello A, Prencipe RS, Breda C, Staffieri A, Rinaldi R (2010) Deep neck abscess due to Acinetobacter baumannii infection. Am J Otolaryngol 31(4):304–307.

    Article  PubMed  Google Scholar 

  10. McConnell MJ, Pérez-Ordóñez A, Pérez-Romero P, Valencia R, Lepe JA, Vázquez-Barba I, Pachón J (2012) Quantitative real-time PCR for detection of Acinetobacter baumannii colonization in the hospital environment. J Clin Microbiol 50(4):1412–1414.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Nomanpour B, Ghodousi A, Babaei A, Abtahi HR, Tabrizi M, Feizabadi MM (2011) Rapid, cost-effective, sensitive and quantitative detection of Acinetobacter baumannii from pneumonia patients. Iran J Microbiol 3(4):162–169

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Rice LM, Reis AH Jr, Ronish B, Carver-Brown RK, Czajka JW, Gentile N, Kost G, Wangh LJ (2013) Design of a single-tube, endpoint, linear-after-the-exponential-PCR assay for 17 pathogens associated with sepsis. J App Microbiol 114(2):457–469.

    CAS  Article  Google Scholar 

  13. Soo PC, Tseng CC, Ling SR, Liou ML, Liu CC, Chao HJ, Lin TY, Chang KC (2013) Rapid and sensitive detection of Acinetobacter baumannii using loop mediated isothermal amplification. J Microbiol Meth 92(2):197–200.

    CAS  Article  Google Scholar 

  14. Turton JF, Shah J, Ozongwu C, Pike R (2010) Incidence of Acinetobacter species other than A. baumannii among clinical isolates of Acinetobacter: evidence for emerging species. J Clin Microbiol 48(4):1445–1449.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Van Looveren M, Goossens H (2004) Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect 10(8):684–704.

    Article  PubMed  Google Scholar 

  16. Wang Q, Zhou Y, Li S, Zhuo C, Xu S, Huang L, Yang L, Liao K (2013) Real-time fluorescence loop mediated isothermal amplification for the detection of Acinetobacter baumannii. PLoS ONE 8(7):e66406.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  17. Wang Y, Wang Y, Ma AJ, Li DX, Luo LJ, Liu DX, Jin D, Liu K, Ye CY (2015) Rapid and sensitive isothermal detection of nucleic-acid sequence by multiple cross displacement amplification. Sci Rep 8:11902.

    Article  Google Scholar 

  18. Wang Y, Wang Y, Zhang L, Xu JG, Ye CY (2017) Visual and multiplex detection of nucleic acid sequence by multiple cross displacement amplification coupled with gold nanoparticle-based lateral flow biosensor. Sens Actuators B Chem 241:1283–1293.

    CAS  Article  Google Scholar 

  19. Wang Y, Yan W, Fu S, Hu S, Wang Y, Xu J, Ye C (2018a) Multiple cross displacement amplification coupled with nanoparticles-based lateral flow biosensor for detection of Staphylococcus aureus and identification of methicillin-resistant S. aureus. Front Microbiol 9:907.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Wang Y, Yan W, Wang Y, Xu J, Ye C (2018b) Rapid, sensitive and reliable detection of Klebsiella pneumoniae by label-free multiple cross displacement amplification coupled with nanoparticles-based biosensor. J Microbiol Methods 149:80–88.

    CAS  Article  PubMed  Google Scholar 

  21. Zhang L, Ding G, Wei L, Pan X, Mei L, Zhang Y, Lu Y (2011) Establishment of a novel target-based real-time quantitative PCR method for Acinetobacter baumannii detection. Diagn Mol Pathol 20(4):242–248.

    CAS  Article  PubMed  Google Scholar 

  22. Zhao F, Niu L, Nong J, Wang C, Wang J, Liu Y, Gao N, Zhu X, Wu L, Hu S (2018) Rapid and sensitive detection of Pseudomonas aeruginosa using multiple cross displacement amplification and gold nanoparticle-based lateral flow biosensor visualization. FEMS Microbiol Lett.

    Article  PubMed  Google Scholar 

  23. Zhou HY, Yuan Z, Du YP (2014) Prior use of four invasive procedures increases the risk of Acinetobacter baumannii nosocomial bacteremia among patients in intensive care units: a systematic review and meta-analysis. Int J Infect Dis 22:25–30.

    Article  PubMed  Google Scholar 

Download references

Authors’ contributions

XQC and JY designed the study. MFW, PW, QD and JJH carried out experiments. XQC wrote the manuscript. YJT was responsible for the overall supervision of the study and funded this study. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

All data analysed during this study are included in this manuscript and its supplemental materials.

Consent for publication

Not applicable.


This work was supported by the National Natural Science Foundation of China [Grant Number 81270092] and Educational commission of Hubei Province of China [Grant Numbers Q20112106 and B20122414].

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author information



Corresponding author

Correspondence to Yijun Tang.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Cheng, X., Yang, J., Wang, M. et al. Visual and rapid detection of Acinetobacter baumannii by a multiple cross displacement amplification combined with nanoparticles-based biosensor assay. AMB Expr 9, 30 (2019).

Download citation


  • Acinetobacter baumannii
  • Multiple cross displacement amplification
  • Lateral flow biosensor
  • Detection limit